

## Nanotherapeutics Announces Election of New Directors and Officers

*Weaver H. Gaines, Director and Chairman of the Board*

*James R. Butler, Robert J. Hennessey, and James M. Matthew, Directors*

*Dennis S. Kristof, Treasurer*

*Bärbel Eppler, Ph.D., Secretary*

*James F. Kirk, Ph.D., Vice President R&D*

ALACHUA, Fla.--([BUSINESS WIRE](#))--Nanotherapeutics, Inc., a privately-held specialty biomedical company, announced today that its Board of Directors elected Weaver H. Gaines as the company's new non-Executive Chairman. Mr. Gaines is a serial entrepreneur, with 35 years of executive, legal, and entrepreneurial experience, particularly in early stage companies. He is also a trustee of Torrey Pines Institute of Molecular Studies and a director of the Florida Research Consortium.

In other actions, the Board increased the number of directors to seven and elected James R. Butler, Robert Hennessey, and James M. Matthew as directors. Mr. Butler is a Senior Advisor to Capnia, a director of Invitrox, Sirion Therapeutics, and Respirics (where he is also chairman). Previously he was SVP Sales & Marketing at Reliant Pharmaceuticals and President of Alza International. Mr. Hennessey is Managing Director of Hennessey and Associates and is the former Chairman, President, and CEO and a director of Genome Therapeutics (now Oscient Pharmaceuticals). He was also interim President and CEO of PenWest Pharmaceuticals. Mr. Matthew is the CFO and Secretary of Jessup & Lamont a publicly-held financial services firm. Previously, he was CFO and Secretary of Plan Express and Polyvue Technologies, where he also was a director.

"As the Company has increased the scale and nature of its activities, we needed to expand our board to assist with the strategic implications of our growing complexity. On behalf of the Board, we welcome Weaver as Chairman and Jim and Bob as directors," said James D. Talton, Ph.D., President, CEO, and co-founder of Nanotherapeutics. "Their industry knowledge, experience, and leadership are remarkably rich."

Mr. Gaines said, "We have an exceptionally able management team with experience and insights into early stage product development and an expanded board with a comprehensive set of complementary talents. I look forward to our working together to advance our pipeline through clinical development."

The Board also elected Dennis S. Kristof, CMA, MBA, to the additional office of Treasurer and Bärbel Eppler, Ph.D., to the additional position of Secretary. Mr. Kristof joined Nanotherapeutics in 2006 as Controller, having previously held the similar position at Oragenics, Inc. He is also Vice President of the Florida Association of Bioscience Financial Officers. Dr. Eppler is Vice President of Preclinical Development and QA at Nanotherapeutics.

James F. Kirk, Ph.D., was named Vice President of Research and Development. Dr. Kirk earned his M.S. at the Massachusetts Institute of Technology in polymer science and his Ph.D. at the University of Florida in Materials Science and Engineering, particularly in drug delivery and bio-erodible devices. Most recently he has been consulting with a variety of biomedical companies on materials selection and process development. His career spans work as a research scientist, senior processing engineer, and as director of manufacturing and new product development.

Nanotherapeutics is a privately-held specialty biomedical company with full product development and cGMP manufacturing capabilities and a proprietary pipeline. The Company's technologies can be used with all drug types ranging from small molecules to proteins and peptides. Nanotherapeutics is focused on drug development, not early-stage discovery, and recently launched its first product, Origen DBM, injectable bone graft for orthopedic applications. For more information, visit [www.nanotherapeutics.com](http://www.nanotherapeutics.com).

#### Contacts

Nanotherapeutics  
Weaver H. Gaines, 386-462-3961  
Chairman of the Board

